Patents Represented by Attorney, Agent or Law Firm Bertram I. Rowland
  • Patent number: 5571568
    Abstract: Bioelectronic sensors are provided employing a thin surfactant polymeric electrically conducting layer to which may be bound members of specific binding pairs. Binding of an analyte or a reagent to the specific binding pair member layer may change the electrical, optical, or structural properties of the layer for measurement of analyte. The change in the polymeric layer provides for a sensitive measurement.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 5, 1996
    Assignee: Biocircuits Corporation
    Inventors: Hans O. Ribi, Todd Guion, Paul T. Shafer
  • Patent number: 5571493
    Abstract: Methods for producing a room temperature stable, phase pure .alpha.-C.sub.3 P product, and compositions derived therefrom, are provided. In the subject method, a tricalcium phosphate source is heated to a temperature sufficient to convert substantially all of said tricalcium phosphate source to a substantially phase pure .alpha.-C.sub.3 P product. The temperature of the resultant product is rapidly cooled to a temperature below about 700.degree. C., resulting in a room temperature stable, reactive .alpha.-C.sub.3 P product. The resultant .alpha.-C.sub.3 P product may be milled to provide an .alpha.-C.sub.3 P composition which may find use in the preparation of calcium phosphate cements.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 5, 1996
    Assignee: Norian Corporation
    Inventors: Mark Fulmer, Brent R. Constantz, Ira C. Ison, Bryan M. Barr
  • Patent number: 5569673
    Abstract: N-Acylated catecholmethylamines are used to inhibit cancer cell proliferation. Specifically, capsaicin is found to inhibit growth at low concentration, but not normal cells.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: October 29, 1996
    Assignee: Purdue Research Foundation
    Inventors: D. James Morre, Dorothy M. Morre
  • Patent number: 5569442
    Abstract: Methods for producing a room temperature stable, phase pure .alpha.-C.sub.3 P product, and compositions derived therefrom, are provided. In the subject method, a tricalcium phosphate source is heated to a temperature sufficient to convert substantially all of said tricalcium phosphate source to a substantially phase pure .alpha.-C.sub.3 P product. The temperature of the resultant product is rapidly cooled to a temperature below about 700.degree. C., resulting in a room temperature stable, reactive .alpha.-C.sub.3 P product. The resultant .alpha.-C.sub.3 P product may be milled to provide an .alpha.-C.sub.3 P composition which may find use in the preparation of calcium phosphate cements.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: October 29, 1996
    Assignee: Norian Corporation
    Inventors: Mark Fulmer, Brent R. Constantz, Ira C. Ison, Bryan M. Barr
  • Patent number: 5569364
    Abstract: Separation media for electrophoresis, and methods of filling and flushing of electrophoretic devices such as capillaries are described. By preparing submicron to above-micron sized cross-linked gel particles and using gel swelling equilibrium concepts, such devices can be easily filled and flushed. Gel particles can be prepared by inverse suspension, precipitation and suspension polymerization. These particles can be swollen and collapsed by small changes in temperature, pH, and ionic strength of solvent. Other approaches involve the formation of reversible cross-links by use of polyelectrolyte complexes, chelating agents or copolymers of hydrophobic and hydrophilic repeat units. Finally, reversibly solubilized systems may be used to change the viscosity of the media.
    Type: Grant
    Filed: May 10, 1994
    Date of Patent: October 29, 1996
    Assignee: Soane Biosciences, Inc.
    Inventors: Herbert H. Hooper, Stephen Pacetti, David S. Soane, Young C. Bae
  • Patent number: 5569753
    Abstract: Nucleic acid sequence probes are provided for the detection of lesions associated with neoplastic cells. The sequences can be used for identifying the locus associated with the lesion, for determining cancer susceptibility of cells, as well as categorizing and characterizing tumor cells for prognosis and therapy.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: October 29, 1996
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Michael Wigler, Nikolai Lisitsyn
  • Patent number: 5567729
    Abstract: Farnesyl derivatives, particularly farnesyl acetate, are used to reduce the level of protein farnesylation in a mammalian host. The activity of proteins which require farnesylation for function is thereby reduced. The compounds may be administered to patients to reduce the overall level of ras protein activity, either alone or in conjunction with other drugs which act as competitive inhibitors of farnesyl protein transferase.
    Type: Grant
    Filed: October 28, 1993
    Date of Patent: October 22, 1996
    Assignees: David L. Bradfute, Thomas E. Meigs, Robert D. Simoni
    Inventors: David L. Bradfute, Robert D. Simoni, Thomas E. Meigs
  • Patent number: 5567627
    Abstract: A method for detecting multiple subpopulations of analytes of interest in a sample employing a complementary binding moiety to each of said analytes bound to a solid support, wherein each analyte and its complementary binding moiety comprise first and second members of a specific binding pair (msbp) respectively is provided. The method includes the steps of forming a mixture of known proportions of multiple subpopulations of said complementary binding moieties, wherein each subpopulation comprises a different complementary binding moieties, contacting the sample with the mixture so that specific binding pairs are formed on the solid supports, and relating the presence of analytes of interest in the sample to the formation of specific binding pairs associated with each unique proportion of said multiple subpopulations. The method can be performed with solid supports of a single average size and a single fluorochrome and without the need for using three detection systems (fluorescence FS & SS).
    Type: Grant
    Filed: November 5, 1993
    Date of Patent: October 22, 1996
    Assignee: Trans-Med Biotech, Incorporated
    Inventor: Brian C. Lehnen
  • Patent number: 5565554
    Abstract: Novel fluorescent DNA-staining dyes are provided combining asymmetric cyanine azole-indolenine dyes, which provide for strong DNA affinity, large Stokes shifts and emission in the red region of the spectrum. The dyes find particular application in gel electrophoresis and for labels which may be bound to a variety of compositions in a variety of contexts.
    Type: Grant
    Filed: July 29, 1994
    Date of Patent: October 15, 1996
    Assignee: The Regents of the University of California
    Inventors: Alexander N. Glazer, Scott C. Benson
  • Patent number: 5563035
    Abstract: ERF-1 is shown to be a transcriptional regulator of the expression of the estrogen receptor, where elevated ERF-1 is related to elevated expression of the estrogen receptor. By monitoring the level of ERF-1, one can relate phenotypic characteristics of carcinomas expressing ERF-1 as prognostic of the response of the tumor to various therapies. In addition, ERF-1 may be used for screening therapeutic drugs which may act as antagonists to initiation of estrogen receptor transcription.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: October 8, 1996
    Assignee: The Board of Trustees of The Leland Stanford Junior University
    Inventor: Ronald J. Weigel
  • Patent number: 5556780
    Abstract: An angiotensin II type 2 receptor (AT.sub.2 receptor), structurally related cell receptors, nucleic acids encoding such AT.sub.2 receptors, AT.sub.2 receptor-related peptides, and methods of using AT.sub.2 receptors and AT.sub.2 receptor-encoding nucleic acids are provide. AT.sub.2 receptor-specific binding compounds are disclosed including antibodies to AT.sub.2 receptor epitopes. The invention provides AT.sub.2 receptor-based pharmaceutical compositions and AT.sub.2 receptor-based methods rot screening chemical libraries for regulators of cell growth/differentiation. In particular, the invention provides methods for identifying agonists and antagonists of the disclosed AT.sub.2 receptor. Such compositions find broad utility in the treatment of cardiovascular disease, cancer, reproductive disease, etc.
    Type: Grant
    Filed: November 5, 1993
    Date of Patent: September 17, 1996
    Assignee: The Board of Trustees for the Leland Stanford Junior University
    Inventors: Victor Dzau, Masahi Mukoyama
  • Patent number: 5552537
    Abstract: Methods and compositions are provided relating to novel IgE isoforms and their use in immune hypersensitivity diagnosis and treatment. The compositions include transcription and translation products of the immunoglobulin epsilon locus, specific probes for epsilon transcription products, and compounds which specifically bind epitopes of epsilon translation products. Novel products of the epsilon locus include the following transcription products and translation products thereof: CH4-M2", SEQ ID NO:02, residues 1-107 and, (SEQ. ID NO:06, CH4'-CH5-M1'-M2, (see SEQ ID NO:02, residues 1-72,SEQ ID NO:03 and SEQ ID NO:05) CH4'-CH5-M2'(SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:07 and CH4'-CH5-M2" (SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:06). Such epsilon products, specific probes and binding compounds find use in methods and kits for immune hypersensitivity diagnosis and treatment.
    Type: Grant
    Filed: March 24, 1993
    Date of Patent: September 3, 1996
    Assignee: The Regents of the University of California
    Inventors: Andrew Saxon, Ke Zhang, Edward E. Max
  • Patent number: 5550054
    Abstract: Novel hematopoietic-restricted tyrosine kinases are provided, where the tyrosine kinases provide for autophosphorylation and transphosphorylation. Modulation of the activity of the subject compositions can be used to restrict growth and differentiation, to correct genetic deficiencies, and to elucidate the activation pathway involved with the subject tyrosine kinases. In addition, the tyrosine kinases may be used in a variety of assays as a label or in the production of the phosphorylated peptides.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: August 27, 1996
    Assignee: The Regents of the University of California
    Inventors: Owen Witte, Satoshi Tsukada, Douglas Saffran, David Rawlings
  • Patent number: 5547844
    Abstract: Chemotactin, diethyl phthalate, is shown to be a chemoattractant secreted by H. pylori. Chemotactin attracts phagocytic cells with a resulting inflammatory episode. Chemotactin and its metabolites may be used for diagnosis and monitoring courses of infection by H. pylori or other chemotactin secreting organisms. In addition, chemotactin may be used in research for studying the inflammatory process, for identifying new drugs for modulating chemoattraction and activation of phagocytic cells, and for inducing an inflammatory response as a therapeutic intervention.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: August 20, 1996
    Assignee: The Regents of the University of California
    Inventors: Peter A. Anton, Joseph R. Reeve, Jr., John H. Walsh, Kym F. Faull
  • Patent number: 5538722
    Abstract: Myoblasts are produced, conveniently in low or serum-free medium, for use in introduction into a mammalian host, particularly a human host, for treatment of diseases of muscle tissue or acting as carriers for genetic capabilities, particularly correcting a genetic defect or for production of a soluble protein, which may serve in a therapy for the mammalian host. Myoblasts introduced into tissue are able to migrate to sites distal from the site of injection, expanding the area of their effect.
    Type: Grant
    Filed: August 22, 1991
    Date of Patent: July 23, 1996
    Assignee: Stanford University
    Inventors: Helen M. Blau, Simon M. Hughes
  • Patent number: 5538724
    Abstract: Methods and compositions are described for modulating trafficking of leukocytes to endothelial cells involving the binding of homing receptors and addressins. Particularly, compositions are provided which can inhibit the interaction between the homing receptor and addressin or provide for directing specific molecules associated with diagnosis or treatment, where the molecules bind to the addressins.
    Type: Grant
    Filed: December 19, 1991
    Date of Patent: July 23, 1996
    Assignee: The Board of Trustees for the Leland Stanford Junior Univ.
    Inventors: Eugene C. Butcher, Philip R. Streeter, Ellen L. Berg
  • Patent number: 5538713
    Abstract: Primordial tissue is introduced into immunodeficient hosts, where the primordial tissue develops and differentiates. The chimeric host allows for investigation of the processes and development of the xenogeneic tissue, testing for the effects of various agents on the growth and differentiation of the tissue, as well as identification of agents involved with the growth and differentiation.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 23, 1996
    Assignee: Systemix, Inc.
    Inventor: Bruno P eault
  • Patent number: 5534412
    Abstract: Methods and compositions are provided for the determination of cross-reactive alleles, where there is no antibody which will specifically distinguish between the two alleles. Particularly, the method employs an antibody which binds to the two alleles bound to a surface, an antibody specific for one of the alleles, a labeled conjugate which binds to a consensus sequence present in both alleles and positive and negative controls. By having an enhanced value where the interfering allele is present as compared to a value for the target allele, one can distinguish between the various alternatives involving the presence or absence of one or both alleles.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: July 9, 1996
    Assignee: SangStat Medical Corporation
    Inventors: Philippe Pouletty, Chin-Hai Chang
  • Patent number: 5532265
    Abstract: A synthetic inhibitor of matrix metalloproteases, the tripeptide hydroxamate GM 6001, is administered to a patient suffering from an inflammatory disease of the central nervous system wherein the effect is mediated primarily through restoration of the blood-CNS barrier.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: July 2, 1996
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Koenraad Gijbels, Lawrence Steinman
  • Patent number: 5523227
    Abstract: DNA and protein compositions are provided for calcium-signal modulating cyclophilin ligand which are shown to act in the calcium-dependent pathway for activation of a number of genes. The DNA composition and proteins may be used in investigating the processes associated with calcium-dependent activation of genes, as well as screening of drugs for interaction with the subject proteins for modulating cell processes, e.g. T-cell activation.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: June 4, 1996
    Assignee: The Board of Trustees of the Leland Stanford Junior Univ.
    Inventors: Richard J. Bram, Gerald R. Crabtree